Developer docs
API playgroundTry for free, no card

Search company profiles

Calluna Pharma

Full company profile

uuid0000h5x

Namestring
Calluna Pharma
Legal namestring
Calluna Pharma
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Calluna Pharma is a clinical-stage biotechnology company headquartered in Oslo, Norway, with an additional presence in Boston, Massachusetts. Formed in 2023 through the merger of Oxitope Pharma and Arxx Therapeutics and financed in January 2024 with a EUR 75 million Series A led by Forbion, the company is developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers — specifically damage-associated molecular pattern (DAMP) proteins and oxidized phospholipids (OxPLs) — to address chronic inflammation and fibrosis at the source rather than modulating downstream mediators.

Its pipeline is anchored by CAL101, a humanized anti-S100A4 monoclonal antibody currently being evaluated in the Phase 2 AURORA study in idiopathic pulmonary fibrosis (IPF) and positioned for additional fibrotic indications such as systemic sclerosis. The company's second program, CAL103, targets oxidized phospholipids for chronic inflammatory and respiratory conditions, including COPD and rheumatoid arthritis, and is being advanced through a co-development partnership with Lilly ExploR&D. The platform is supported by over 30 years of co-founder research, peer-reviewed publications, and regulatory milestones including FDA Orphan Drug Designation for CAL101 in IPF (October 2025).

Calluna is pre-revenue and does not yet commercialize any product. Its value-creation model is the standard clinical-stage biotech playbook: advance candidates through clinical development, secure regulatory designations, and ultimately generate revenue through product sales upon approval or via licensing/royalty agreements such as the existing CAL103 arrangement with Lilly. The company targets approximately 233,000 IPF patients in the US and EU, a market estimated at roughly $3 billion in 2025 and growing toward nearly $7 billion by 2035. Topline Phase 2 data from AURORA (161 patients enrolled across 50+ sites) are expected in Q1 2027.

Short descriptiontext

Calluna Pharma is a clinical-stage biotech developing first-in-class monoclonal antibodies (CAL101 targeting S100A4 for IPF; CAL103 targeting OxPL for inflammatory diseases) that address upstream drivers of inflammation and fibrosis, serving patients with serious fibrotic and chronic inflammatory conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, fibrotic disease treatments, monoclonal antibody development, inflammatory disease therapeutics, clinical-stage biotechnology
Industry3 codes
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development & Licensing
TypeLicensing Royalties
Description

Calluna Pharma is a pre-revenue clinical-stage biotechnology company. Its primary value creation comes from developing novel therapeutic candidates through clinical trials and out-licensing or commercializing resulting products. Revenue will ultimately derive from product sales upon regulatory approval, with potential milestone payments from partnerships such as the existing CAL103 partnership with Lilly ExploR&D.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Calluna Pharma is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers (the DAMP protein S100A4 and oxidized phospholipids) to treat chronic inflammatory and fibrotic diseases. Its lead candidate CAL101 is in Phase 2 development for idiopathic pulmonary fibrosis (IPF), while CAL103 is being co-developed with Lilly ExploR&D for chronic inflammatory indications such as COPD and rheumatoid arthritis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 1 study in 57 subjects: favorable safety profile with no Serious Adverse Events across all doses; balanced frequency and types of AEs vs placebo; favorable PK with dose-dependent increases in exposure supporting once monthly dosing; very low anti-drug antibody titers with no impact on PK and safety; complete target coverage at clinically relevant doses
+2 more records
Product overview1 text field

Calluna Pharma is a clinical-stage biotechnology company pioneering first-in-class therapeutic antibodies to treat inflammatory and fibrotic diseases. The company's pipeline consists of CAL101 (targeting S100A4 for idiopathic pulmonary fibrosis, currently in Phase 2) and CAL103 (targeting oxidized phospholipids for chronic inflammatory conditions, in preclinical/early development). These antibodies leverage over 30 years of research to target upstream innate immune amplifiers, modulating disease-associated signaling pathways while ensuring a favorable safety profile.

Product and service2 records
1CAL101
CategoryAnti-fibrotic monoclonal antibody therapeutic
2CAL103
CategoryAnti-inflammatory monoclonal antibody therapeutic
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-01-23
Description

The Phase 1 first-in-human study of CAL101 was led by Professor Dave Singh at the Medicines Evaluation Unit in Manchester, UK. The randomized, double-blind, placebo-controlled study enrolled 57 subjects to evaluate safety, tolerability, immunogenicity, and pharmacokinetics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CAL103 (targeting oxidized phospholipids) is listed 'In partnership with Lilly ExploR&D' in Calluna Pharma's pipeline, indicating a co-development or licensing partnership for the CAL103 program targeting chronic inflammatory and respiratory conditions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed pamrevlumab for IPF through late-stage trials; same lead indication as Calluna and serves as the most relevant cautionary comparable for clinical-stage IPF assets.

TypeBroad incumbent
Description

European biopharma with historical IPF pipeline (ziritaxestat failed, but retained fibrosis interests); relevant broad peer given European footprint and inflammation/fibrosis focus.

TypeDirect peer
Description

Clinical-stage biotech developing integrin-targeting therapies for IPF and fibrotic diseases; bexotegrast is in Phase 2b/3 for IPF, making it the most directly comparable late-stage fibrosis peer to Calluna.

TypeEmerging player
Description

Swedish clinical-stage biotech developing buloxibutid (C21) for IPF; European geographic peer with similar clinical-stage positioning and IPF lead indication.

5Blade Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing calpain inhibitors for IPF and other fibrotic diseases; smaller peer with overlapping fibrosis indications and similar development stage.

TypeBroad incumbent
Description

Markets Tyvaso, an approved therapy used in PH-ILD and related fibrotic lung indications; a competing commercial player in the broader fibrotic lung disease space.

7Boehringer Ingelheim (Ofev franchise)
TypeBroad incumbent
Description

Markets Ofev (nintedanib), the leading approved IPF therapy; defines the efficacy and safety benchmark any new entrant such as CAL101 must beat or match.

TypeDirect peer
Description

Clinical-stage biotech developing inhaled pirfenidone (AP01) for IPF; competing directly for the same patient population with a reformulation strategy and overlapping Phase 2/3 timing.

TypeBroad incumbent
Description

Sold Esbriet (pirfenidone), the other approved IPF therapy and historical standard of care; relevant as the established benchmark Calluna's S100A4 mechanism must outperform.

TypeEmerging player
Description

Clinical-stage biotech developing ENV-101 (taladegib) for IPF; competing in the same Phase 2 IPF indication with a Hedgehog pathway mechanism.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Calluna Pharma

Biopharmaceutical Therapeuticscallunapharma.com

Calluna Pharma is a clinical-stage biotech developing first-in-class monoclonal antibodies (CAL101 targeting S100A4 for IPF; CAL103 targeting OxPL for inflammatory diseases) that address upstream drivers of inflammation and fibrosis, serving patients with serious fibrotic and chronic inflammatory conditions.

What Calluna Pharma does

Calluna Pharma is a clinical-stage biotechnology company headquartered in Oslo, Norway, with an additional presence in Boston, Massachusetts. Formed in 2023 through the merger of Oxitope Pharma and Arxx Therapeutics and financed in January 2024 with a EUR 75 million Series A led by Forbion, the company is developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers — specifically damage-associated molecular pattern (DAMP) proteins and oxidized phospholipids (OxPLs) — to address chronic inflammation and fibrosis at the source rather than modulating downstream mediators.

Its pipeline is anchored by CAL101, a humanized anti-S100A4 monoclonal antibody currently being evaluated in the Phase 2 AURORA study in idiopathic pulmonary fibrosis (IPF) and positioned for additional fibrotic indications such as systemic sclerosis. The company's second program, CAL103, targets oxidized phospholipids for chronic inflammatory and respiratory conditions, including COPD and rheumatoid arthritis, and is being advanced through a co-development partnership with Lilly ExploR&D. The platform is supported by over 30 years of co-founder research, peer-reviewed publications, and regulatory milestones including FDA Orphan Drug Designation for CAL101 in IPF (October 2025).

Calluna is pre-revenue and does not yet commercialize any product. Its value-creation model is the standard clinical-stage biotech playbook: advance candidates through clinical development, secure regulatory designations, and ultimately generate revenue through product sales upon approval or via licensing/royalty agreements such as the existing CAL103 arrangement with Lilly. The company targets approximately 233,000 IPF patients in the US and EU, a market estimated at roughly $3 billion in 2025 and growing toward nearly $7 billion by 2035. Topline Phase 2 data from AURORA (161 patients enrolled across 50+ sites) are expected in Q1 2027.

Calluna Pharma firmographics

Firmographics
Name
Calluna Pharma
Legal name
Calluna Pharma
Website
https://callunapharma.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Calluna Pharma is a clinical-stage biotech developing first-in-class monoclonal antibodies (CAL101 targeting S100A4 for IPF; CAL103 targeting OxPL for inflammatory diseases) that address upstream drivers of inflammation and fibrosis, serving patients with serious fibrotic and chronic inflammatory conditions.
Ownership category
akta.pro rank

Calluna Pharma industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAG
Pulmonary Hypertension & Rare Pulmonary Disease Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Antibody therapeutics
  • Fibrotic disease treatments
  • Monoclonal antibody development
  • Inflammatory disease therapeutics
  • Clinical-stage biotechnology

Where Calluna Pharma is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

Calluna Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development & Licensing: Calluna Pharma is a pre-revenue clinical-stage biotechnology company. Its primary value creation comes from developing novel therapeutic candidates through clinical trials and out-licensing or commercializing resulting products. Revenue will ultimately derive from product sales upon regulatory approval, with potential milestone payments from partnerships such as the existing CAL103 partnership with Lilly ExploR&D.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Calluna Pharma product offering

Product offering

Core offering

Calluna Pharma is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers (the DAMP protein S100A4 and oxidized phospholipids) to treat chronic inflammatory and fibrotic diseases. Its lead candidate CAL101 is in Phase 2 development for idiopathic pulmonary fibrosis (IPF), while CAL103 is being co-developed with Lilly ExploR&D for chronic inflammatory indications such as COPD and rheumatoid arthritis.

Product overview

Calluna Pharma is a clinical-stage biotechnology company pioneering first-in-class therapeutic antibodies to treat inflammatory and fibrotic diseases. The company's pipeline consists of CAL101 (targeting S100A4 for idiopathic pulmonary fibrosis, currently in Phase 2) and CAL103 (targeting oxidized phospholipids for chronic inflammatory conditions, in preclinical/early development). These antibodies leverage over 30 years of research to target upstream innate immune amplifiers, modulating disease-associated signaling pathways while ensuring a favorable safety profile.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAL101
  • CAL103

Quantifiable outcome

  • Phase 1 study in 57 subjects: favorable safety profile with no Serious Adverse Events across all doses; balanced frequency and types of AEs vs placebo; favorable PK with dose-dependent increases in exposure supporting once monthly dosing; very low anti-drug antibody titers with no impact on PK and safety; complete target coverage at clinically relevant doses
  • +2 more outcomes

Companies that use Calluna Pharma

Customer profile

Segments2 records

Ideal customer profiles3 records

Calluna Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Calluna Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Medicines Evaluation Unit (MEU), Manchester, UKminorStrategic or Co-development Partner · 23 January 2024The Phase 1 first-in-human study of CAL101 was led by Professor Dave Singh at the Medicines Evaluation Unit in Manchester, UK. The randomized, double-blind, placebo-controlled study enrolled 57 subjects to evaluate safety, tolerability, immunogenicity, and pharmacokinetics.
  • Lilly ExploR&DcoreStrategic or Co-development PartnerCAL103 (targeting oxidized phospholipids) is listed 'In partnership with Lilly ExploR&D' in Calluna Pharma's pipeline, indicating a co-development or licensing partnership for the CAL103 program targeting chronic inflammatory and respiratory conditions.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Calluna Pharma competitors and assessment

Company assessment

Direct peers

  • FibroGen: Developed pamrevlumab for IPF through late-stage trials; same lead indication as Calluna and serves as the most relevant cautionary comparable for clinical-stage IPF assets.
  • Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting therapies for IPF and fibrotic diseases; bexotegrast is in Phase 2b/3 for IPF, making it the most directly comparable late-stage fibrosis peer to Calluna.
  • Avalyn Pharma: Clinical-stage biotech developing inhaled pirfenidone (AP01) for IPF; competing directly for the same patient population with a reformulation strategy and overlapping Phase 2/3 timing.

Broad incumbents

  • Galapagos NV: European biopharma with historical IPF pipeline (ziritaxestat failed, but retained fibrosis interests); relevant broad peer given European footprint and inflammation/fibrosis focus.
  • United Therapeutics: Markets Tyvaso, an approved therapy used in PH-ILD and related fibrotic lung indications; a competing commercial player in the broader fibrotic lung disease space.
  • Boehringer Ingelheim (Ofev franchise): Markets Ofev (nintedanib), the leading approved IPF therapy; defines the efficacy and safety benchmark any new entrant such as CAL101 must beat or match.
  • Roche (Esbriet franchise): Sold Esbriet (pirfenidone), the other approved IPF therapy and historical standard of care; relevant as the established benchmark Calluna's S100A4 mechanism must outperform.

Emerging players

  • Vicore Pharma: Swedish clinical-stage biotech developing buloxibutid (C21) for IPF; European geographic peer with similar clinical-stage positioning and IPF lead indication.
  • Blade Therapeutics: Clinical-stage biotech developing calpain inhibitors for IPF and other fibrotic diseases; smaller peer with overlapping fibrosis indications and similar development stage.
  • Endeavor BioMedicines: Clinical-stage biotech developing ENV-101 (taladegib) for IPF; competing in the same Phase 2 IPF indication with a Hedgehog pathway mechanism.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Calluna Pharma social profiles

Digital presence

Calluna Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Calluna Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Calluna Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Calluna Pharma M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calluna Pharma

What does Calluna Pharma do?

Calluna Pharma is a clinical-stage biotechnology company developing first-in-class monoclonal antibody therapeutics that target upstream innate immune amplifiers (the DAMP protein S100A4 and oxidized phospholipids) to treat chronic inflammatory and fibrotic diseases. Its lead candidate CAL101 is in Phase 2 development for idiopathic pulmonary fibrosis (IPF), while CAL103 is being co-developed with Lilly ExploR&D for chronic inflammatory indications such as COPD and rheumatoid arthritis.

Is Calluna Pharma a public or private company?

Calluna Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Calluna Pharma founded?

Calluna Pharma was founded in 2023. It employs 11 to 50 people.

Where is Calluna Pharma based?

Calluna Pharma is headquartered in Oslo, Norway, in the Europe region.

How does Calluna Pharma make money?

One revenue line is on record: pharmaceutical Drug Development & Licensing.

Who are Calluna Pharma's main competitors?

Direct peers on record are FibroGen, Pliant Therapeutics and Avalyn Pharma. Broad incumbents are Galapagos NV, United Therapeutics, Boehringer Ingelheim (Ofev franchise) and Roche (Esbriet franchise). Emerging players are Vicore Pharma, Blade Therapeutics and Endeavor BioMedicines.

Does Calluna Pharma have an API?

No public API is recorded for Calluna Pharma.

What industry is Calluna Pharma in?

Calluna Pharma's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIAIAG, Pulmonary Hypertension & Rare Pulmonary Disease Therapies, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogCalluna Pharma Announces Participation in Upcoming Scientific and Investor ConferencesCalluna Pharma will present its Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis at the European Respiratory Society Congress in Barcelona and the Wells Fargo Healthcare Conference in Boston in September 2026. The study's readout is planned for Q1 2027.FinancialContent Business PageCalluna Pharma Announces Participation in Upcoming Scientific and Investor ConferencesCalluna Pharma will present its Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis at the ERS Congress and Wells Fargo conference in September 2026. The study's planned Q1 2027 readout is highlighted, with the company also participating in a virtual immunology summit.BioSpaceIPF draws investor heat as biotechs target fibrosis halt, better tolerabilitySeveral biotech companies are developing novel therapies for idiopathic pulmonary fibrosis (IPF) that aim to halt disease progression rather than merely slow it, as current approved treatments like Ofev and Esbriet do. Calluna Pharma announced completed enrollment for its Phase II AURORA study of CAL101, a therapy targeting the S100A4 protein, while Tribune Therapeutics is developing preclinical candidates targeting CCN protein family signaling pathways. The global IPF market generated nearly $3 billion in 2025 and is estimated to reach nearly $7 billion by 2035, with companies viewing IPF as a gateway indication for broader fibrotic diseases including kidney and liver fibrosis.Longevity.TechnologyCalluna completes enrollment in Phase 2 AURORA studyCalluna Pharma completed enrollment in its Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis, enrolling 161 adult patients across over 50 sites. The randomized, double-blind, placebo-controlled trial used a 3:2 randomization and followed a 28-day screening period, with enrollment finishing more than six months ahead of schedule. Calluna anticipates topline data in the first quarter of 2027.Longevity.TechnologyLongevity.TechnologyThe article reports multiple scientific and medical advancements and milestones by various companies, such as Calluna Pharma completing enrollment in a Phase 2 study and Insilico Medicine nominating a preclinical candidate. It also mentions other companies' progress in clinical trials, patent licensing, regulatory fast-track approvals, and product completions.Clinical Trials ArenaCalluna concludes patient enrolment in Phase II trial for IPFCalluna Pharma concluded enrolment in its Phase II AURORA trial for CAL101 in idiopathic pulmonary fibrosis, enrolling 161 adults across over 50 sites. The trial randomizes patients 3:2 to CAL101 or placebo over six months, with topline data expected in Q1 2027.BioSpaceCalluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)Calluna Pharma completed enrollment in its Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis, enrolling 161 patients across 50+ sites. The randomized, double-blind, placebo-controlled trial is six months ahead of schedule, with topline data expected in Q1 2027.PharmiWeb.comCalluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent DirectorCalluna Pharma AS, a clinical stage biotechnology company based in Oslo, Norway, announced the appointment of Gijs van den Brink, MD, PhD, as an independent director to its Board of Directors. Dr. van den Brink brings over two decades of immunology research and drug development experience, having previously served as SVP and Global Head of Immunology at Roche and GSK. He currently serves as chief scientific officer of Granite Bio and as an Operating Partner at Forbion.Business Wire BlogCalluna Pharma Announces the Appointment of Gijs van den Brink, MD, PhD, as Independent DirectorCalluna Pharma AS, a clinical stage biotechnology company based in Oslo, Norway, announced the appointment of Gijs van den Brink, MD, PhD, as an independent director to its Board of Directors. Dr. van den Brink brings extensive immunology research and drug development experience, having previously served as SVP and Global Head of Immunology at both Roche and GSK, and currently holds positions as chief scientific officer of Granite Bio and Operating Partner at Forbion. The company stated that his expertise is expected to strengthen its mission to advance treatments for inflammatory and fibrotic diseases.YahooCalluna Pharma Announces U.S. FDA Orphan Drug Designation Granted to CAL101 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)Calluna Pharma received U.S. FDA orphan drug designation for CAL101, a monoclonal antibody targeting S100A4, for idiopathic pulmonary fibrosis. The designation supports the ongoing AURORA Phase 2 study, which will enroll 150 patients across 50+ sites. The company may pursue expedited review and market exclusivity.